News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Policy
US FDA Staff Mixed on AstraZeneca PLC Drug, Brilinta
July 27, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Reuters -- U.S. reviewers gave mixed views on AstraZeneca Plc's (AZN.L) experimental blood thinner but the company's shares rose on investor optimism that an advisory panel will back the potential blockbuster drug.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
AstraZeneca Pharmaceuticals LP
Food and Drug Administration (FDA)
MORE ON THIS TOPIC
Podcast
FDA Layoffs, 200 Rejection Letters, User Fees and Priority Vouchers, Bad Week for Rare Disease
July 16, 2025
·
1 min read
·
Heather McKenzie
Layoffs
HHS Begins Formally Laying Off Employees
July 15, 2025
·
2 min read
·
Tristan Manalac
Policy
FDA Commissioner Marty Makary Proposes Lowering Industry User Fees
July 15, 2025
·
2 min read
·
Tristan Manalac
Drug Development
The Gap Between the Administration’s Pro-Innovation Words and Policy
July 14, 2025
·
6 min read
·
Lori Ellis